Treating Early-Stage Node-Negative Triple-Negative Breast Cancer

Opinion
Video

Ruth M. O'Regan, MD, and Anna Weiss, MD, join the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the treatment of early-stage node-negative triple-negative breast cancer (TNBC).

Recent Videos
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content
Data from the INAVO120 trial support the approval of the inavolisib combination for those with PIK3CA-mutant breast cancer.

FDA Approves Inavolisib Combo in PIK3CA+ Advanced Breast Cancer

Russ Conroy
October 10th 2024
Article

Data from the INAVO120 trial support the approval of the inavolisib combination for those with PIK3CA-mutant breast cancer.

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Applying Updated Breast Cancer Findings From ASCO to Clinical Practice

Neil M. Iyengar, MD;Paolo Tarantino, MD
June 17th 2024
Podcast

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Investigators report no grade 4 adverse effects among patients who received elacestrant/abemaciclib in the phase 1b/2 ELECTRA trial.

Elacestrant Combo Shows Activity, Tolerability in Metastatic Breast Cancer

Jax DiEugenio
October 6th 2024
Article

Investigators report no grade 4 adverse effects among patients who received elacestrant/abemaciclib in the phase 1b/2 ELECTRA trial.

Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.

Finding a Place for Exercise Oncology in the Treatment of Breast Cancer

Neil M. Iyengar, MD
May 20th 2024
Podcast

Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.

Use of DCISionRT may open new options for tailored treatments among patients with HER2-positive ductal carcinoma in situ.

Biosignature Test May Predict Residual Risk Post-BCS/RT in HER2+ DCIS

Russ Conroy
October 2nd 2024
Article

Use of DCISionRT may open new options for tailored treatments among patients with HER2-positive ductal carcinoma in situ.

Data from DESTINY-Breast06 support the priority review designation for T-DXd as a treatment for HER2-low or HER2-ultralow breast cancer.

T-DXd Earns FDA Priority Review in Pretreated HER2-Low Breast Cancer

Russ Conroy
October 1st 2024
Article

Data from DESTINY-Breast06 support the priority review designation for T-DXd as a treatment for HER2-low or HER2-ultralow breast cancer.